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ABSTRACT
Juvenile Myelomonocytic Leukemia (JMML) is a pediatric myeloproliferative 
neoplasm (MPN) that has a poor prognosis. Somatic mutations in Ptpn11 are the 
most frequent cause of JMML and they commonly occur in utero. Animal models of 
mutant Ptpn11 have probed the signaling pathways that contribute to JMML. However, 
existing models may inappropriately exacerbate MPN features by relying on non-
hematopoietic-restricted Cre-loxP strains or transplantations into irradiated recipients. 
In this study we generate hematopoietic-restricted models of Ptpn11E76K-mediated 
disease using Csf1r-MCM and Flt3Cre. We show that these animals have indolent MPN 
progression despite robust GM-CSF hypersensitivity and Ras-Erk hyperactivation. 
Rather, the dominant pathology is pronounced thrombocytopenia with expanded 
extramedullary hematopoiesis. Furthermore, we demonstrate that the timing of 
tamoxifen administration in Csf1r-MCM mice can specifically induce recombinase 
activity in either fetal or adult hematopoietic progenitors. We take advantage of 
this technique to show more rapid monocytosis following Ptpn11E76K expression 
in fetal progenitors compared with adult progenitors. Finally, we demonstrate that 
Ptpn11E76K results in the progressive reduction of T cells, most notably of CD4+ and 
naïve T cells. This corresponds to an increased frequency of T cell progenitors in the 
thymus and may help explain the occasional emergence of T-cell leukemias in JMML 
patients. Overall, our study is the first to describe the consequences of hematopoietic-
restricted Ptpn11E76K expression in the absence of irradiation. Our techniques can be 
readily adapted by other researchers studying somatically-acquired blood disorders.
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INTRODUCTION
Juvenile Myelomonocytic Leukemia is a pediatric 
myeloproliferative neoplasm (MPN) that has limited 
therapeutic options and a poor prognosis. The majority 
of JMML cases are the result of somatic mutations 
in Ras signaling mediators. Hematopoietic-restricted 
Ptpn11 mutations are found in 10–37% of JMML 
patients and are the most frequent polymorphism in 
this disease [1–3]. Mutant Ptpn11 evokes hyperactive 
Ras signaling among hematopoietic progenitors that 
causes growth hypersensitivity in the presence of the 
cytokine GM-CSF [4]. Patients develop monocytosis, 
anemia, thrombocytopenia, and hepatosplenomegaly. 
The only definitive treatment for JMML is an allogeneic 
hematopoietic stem cell (HSC) transplant. Nevertheless, 
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within 5 years of transplant 33% of patients will relapse 
and their overall survival is 52% [5]. 
Historically, the majority of JMML-initiating 
mutations were thought to be mutually exclusive [6, 7]. 
Recent evidence, however, has identified that many 
patients have cooperative mutations in Ras-mediated 
pathways [1–3].  Nevertheless, a single mutation is 
sufficient to give rise to JMML. As such, animal models 
of JMML have been readily generated that utilize 
transplantation of mutation-expressing hematopoietic 
progenitors or Cre-loxP conditional gene targeting [8–
14]. These approaches, however, have notable drawbacks. 
First, post-transplant hematopoiesis is markedly 
different from unperturbed hematopoiesis. Transplanted 
progenitors have altered lifespans, biased differentiation 
potentials, and frequently give rise to different disease 
manifestations when compared with progenitors in non-
transplanted hosts [15–17]. Second, whereas somatic 
JMML mutations are restricted to hematopoietic cells, the 
majority of Cre stains used in the study of JMML have 
promiscuous tissue activity. In addition to their activity 
in the hematopoietic lineage, VavCre is also expressed 
in endothelial cells, LysMcre is also expressed in lung 
stromal cells, and Mx1Cre is also expressed in endothelial 
cells, BM mesenchymal cells, and in the GI tract [18, 19]. 
Hyperactive Ras expression in these non-hematopoietic 
tissues exacerbates features of MPN and leads to solid-
tissue tumors [18–20]. There is a need, therefore, to 
develop animal models of JMML that can more accurately 
recapitulate the pathogenesis of the childhood disease.
The origin of JMML is tightly associated with 
development. The median age at diagnosis is less than 
2 years and the disease bears distinct features of fetal 
hematopoiesis including an overabundance of fetal 
hemoglobin and a unique gene expression signature 
[21, 22]. Furthermore, fetal progenitors have greater 
myeloid colony forming potential compared to adult 
progenitors, suggesting a mechanism whereby they 
may rapidly give rise to a myeloid disease [23]. Finally, 
retrospective testing of patient tissues collected at birth 
suggests that the majority of somatic JMML-initiating 
mutations occur prenatally [3, 24, 25]. We have recently 
shown that in utero expression of the JMML-initiating 
KrasG12D mutation results in a remarkably faithful 
disease model [26]. However, the relative contribution 
of fetal vs. adult progenitors to JMML remains unknown. 
We therefore sought to develop a strategy to induce 
hematopoietic-restricted Ptpn11E76K expression in fetal 
or adult progenitors in the absence of myeloablation. 
We hypothesized that fetal progenitors expressing 
Ptpn11E76K would demonstrate faithful disease 
progression and reveal previously underappreciated 
features of this disease.
In this study we generated hematopoietic-
restricted models of Ptpn11E76K that do not rely on 
transplantation. We performed serial peripheral  blood 
analysis to determine the progression of the disease 
in a non-myeloablated host. Finally, we developed 
a strategy that induces Ptpn11E76K expression in 
either fetal or adult hematopoietic progenitors and we 
compared MPN outcomes following in utero vs. postnatal 
oncogene expression. We have thereby generated faithful 
representations of JMML pathophysiology that can serve 
as pre-clinical models. Moreover, we have identified a 
previously unappreciated paucity of T cells in the setting 
of mutant Ptpn11E76K. This findings corresponds with 
altered T cell development in the thymus of mutant mice 
and may help explain reports of T-ALL emergence in 
JMML patients. 
RESULTS
We confirmed the hematopoietic-restricted 
expression of Flt3Cre using the Rosa26mTomato/
mGFP (mTmG) model [27]. Therein, cells that express 
Cre undergo an irreversible switch from Tomato to 
GFP expression. We measured the frequency of GFP+ 
cells among BM stromal populations in 4 week old 
mice using flow cytometry. As expected, the majority 
of CD45+ BM cells were GFP+, indicating robust Cre 
recombinase activity in this population (Figure 1A). 
In contrast, endothelial cells (Ter119- CD45- CD31+ 
Sca1+), osteoblasts (Ter119- CD45- CD31- CD140a+ 
Sca1-) and mesenchymal progenitor cells (Ter119- CD45- 
CD31- CD140a+ Sca1+) were Tomato+. This confirms 
that Flt3Cre is not active in BM stromal progenitors and 
strongly suggests that this Cre is hematopoietic-restricted. 
We therefore proceeded to mate Flt3Cre+; Rosa26mTmG/
mTmG mice and Ptpn11E76K mice to generate 
Flt3Cre+;Rosa26mTmG/+; Ptpn11E76K/+ (Flt3Cre+; 
E76K) mutants and Flt3Cre+;Rosa26mTmG/+;Ptpn11+/+ 
(Flt3Cre+; WT) controls.
Flt3Cre+;E76K mutants were born at expected 
Mendelian ratio and had markedly myeloid-biased 
peripheral leukocytes beginning at 5weeks of age 
compared to littermate controls (Figure 1B, 1D). There was 
a concomitant decrease in T cells without changes in the 
frequency of B cells. The relative frequency of peripheral 
myeloid cells, B cells, and T cells did not change between 
5–48 weeks of age, at which time there was a pronounced 
increase in myeloid cells and a concomitant decrease in 
B cells (Figure 1E, 1F). The CD4:CD8 ratio among T cells 
in mutants was equal to that in controls until 32 weeks 
of age. Thereafter, mutants show a preferential decrease 
in CD4+ T-cells (Supplementary Figure 1). Whereas 
mutant mice also had a pronounced thrombocytopenia 
and progressive anemia, there was no clear trend towards 
leukocytosis (Figure 1C, 1G, 1H). This suggested that 
Flt3Cre+; E76K mice would have prolonged survival 
compared with previous mouse models that expressed this 
oncogene. Indeed, the median survival of Flt3Cre+;E76K 
mice was 66 weeks of age, compared with historic median 
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survivals of 36 weeks for LysMCre+;E76K mice and 
28 weeks for Mx1Cre+;E76K mice, respectively [11] 
(Figure 1I). These results suggest that in the absence of 
stromal cell expression the MPN initiated by Ptpn11E76K 
demonstrates indolent progression.
Flt3Cre is active in fetal multipotent progenitors 
beginning in utero at around E10.5. However, Flt3Cre 
activity will continue to emerge in MPPs after 4 weeks 
of age, which marks the end of the transition from fetal 
to adult hematopoiesis [28]. As such, this Cre strain 
cannot discern the distinct contribution of fetal and 
adult hematopoietic programs to Ptpn11E76K-mediated 
disease in aged mice. Given that the majority of JMML 
patients have a fetal-like gene expression signature, we 
set out to identify a Cre strain that could uniquely activate 
Ptpn11E76K expression in either the fetal or the adult 
hematopoietic programs.
To this end, we characterized the fluorescence 
expression pattern in Csf1r Mer-Cre-Mer;Rosa26YFP mice 
(Figure 2). In this model, recombinase activity requires 
two simultaneous signals. First, cells must express Csf1r. 
Second, they must be exposed to tamoxifen, which will 
bind the MER domains and permit the nuclear localization 
of the Cre enzyme. We reasoned that by timing the dose 
of tamoxifen we would be able to activate recombinase 
activity in either fetal or adult hematopoietic progenitors. 
We injected 4 week old Csf1r-MCM+; Rosa26YFP 
mice with 3 doses of 75 µg/g tamoxifen. 7 days later, 
we measured the expression of YFP in hematopoietic 
progenitor subsets. Whereas no YFP+ cells were observed 
Figure 1: Flt3Cre+ Ptpn11E76K mice acquire an indolent MPN. (A) Cre activity as measured by GFP expression in BM subsets 
of 4 week old Flt3Cre+ Rosa26mTomato/mGFP mice (n = 3). (B) Birth ratios of Flt3Cre+ x Ptpn11E76K/+ matings with chi-squared analysis (C–H) 
Serial peripheral blood analysis of leukocytes frequency and lineage distribution, platelet count and hemoglobin abundance in mutants 
(n = 10) and littermate controls (n = 12). Percentages represent each lineage’s proportion among all mononuclear cells. P-values represent 
t-tests between mutants and controls. (I) Kaplan–Meier survival analysis of mutants (n = 15) and littermates (n = 18). EC, endothelial cells. 
MSPC, mesenchymal stem/progenitor cell. OB, osteoblast.
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in Cre- littermate controls, Csf1r-MCM+ mice consistently 
had YFP+ LK and LSK cells in the BM and spleen, 
including LSK CD34- CD135- HSCs (Figure 2A, 2B, 2D). 
Furthermore, we observed YFP+ early thymic progenitors 
(CD4- CD8- CD25- CD44+ cKit+) in Csf1r-MCM+ mice 
(Figure 2E). Importantly, very few BM stromal cells – 
such as endothelial cells, osteoblasts, and mesenchymal 
progenitors – were YFP+ (Figure 2C). These findings 
confirm that exposure of Csf1r-MCM+ mice to tamoxifen 
at 4 weeks of age would consistently target hematopoietic 
progenitors of the adult phase.
To determine whether a similar strategy could 
be used to target fetal hematopoietic progenitors, we 
performed timed matings between Csf1r-MCM+ studs 
and Rosa26YFP/YFP dams. At E14.5, pregnant dams were 
injected with 75 µg/g 4-hydroxy tamoxifen. 48 hours later, 
hematopoietic progenitors were isolated from the livers 
of fetuses and YFP expression was measured using flow 
cytometry. We observed consistent YFP+ expression in 
LSK cells, including LSK CD150+ CD48- fetal HSCs, 
in Csf1r-MCM+ embryos (Supplementary Figure 2). 
No YFP+ cells were observed in Cre- littermates. These 
findings suggest that timed exposure of Csf1r-MCM 
mice to tamoxifen would permit specific and consistent 
activation of recombinase activity in either fetal or adult 
hematopoietic progenitors. Additionally, it suggested that 
cells expressing mutant Ptpn11 could be identified via the 
expression of YFP.
We proceeded to generate fetal and adult 
cohorts of Csf1r-MCM+;Rosa26YFP; Ptpn11E76K 
(Csf1r-MCM+;E76K) animals that had been exposed 
to tamoxifen at either E14.5 or at 4 weeks of age, 
respectively. We performed peripheral blood analysis of 
mutant animals and Csf1r-MCM+;RosaYFP;Ptpn11+/+ 
(Csf1r-MCM+;WT) littermate controls (Figure 3). Mutant 
animals in the adult cohort did not demonstrate consistent 
leukocytosis (Figure 3A). Whereas the animals did acquire 
thrombocytopenia, they were only moderately anemic 
(Figure 3B, 3C). Surprisingly, adult-cohort mutants 
showed markedly delayed monocytosis beginning 44 
weeks after tamoxifen, as measured by %CD11b+ cells. 
This coincided with a decline in the frequency of T cells—
as measured by CD3+, CD4+, or CD8+ cells—without 
a change in B220+ B cell frequency (Figure 3D–3F, 
Supplementary Figures 3, 4).
We compared these findings to Csf1r-MCM+;E76K 
mutants whose oncogene became active in utero at E14.5 
(Figure 3G–3L). Mutants in this fetal cohort showed 
monocytosis beginning at 8 weeks of age—considerably 
sooner than mutants in the adult cohort (Figure 3J). 
Nevertheless, this degree of myeloid-biased differentiation 
was small with minimal changes in the frequencies of T 
cells and B cells up to 52 weeks of age (Figure 3K–3L). 
These mutants had neither anemia nor leukocytosis albeit 
they also acquired thrombocytopenia at an early age 
(Figure 3G–3I).
Figure 2: Csf1r MER-Cre-MER activity in hematopoietic progenitors and BM stromal cells. Csf1r-MCM+ Rosa26YFP 
animals were analyzed 1week after injections with tamoxifen. (A–B) Frequency of YFP+ BM and splenic progenitors. (C) Frequency of 
YFP+ BM stromal populations. (D) Analysis of YFP+ BM progenitors in Csf1r-MCM+ Rosa26YFP animals. (E) Frequency of YFP+ thymus 
progenitors. LK, Lin- cKit+. LSK, Lin- Sca1+ cKit+. EC, endothelial cells. MSPC, mesenchymal stem/progenitor cell. OB, osteoblast. 
MDP, myeloid-dendritic progenitor. CMoP, common monocyte progenitor. CMP, common myeloid progenitor, GMP, granulocyte-
macrophage progenitor. MEP, megakaryocyte-erythrocyte progenitor. DP, CD4 CD8 double positive. DN, double negative.
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Despite their indolent progression of MPN, Csf1r-
MCM+;E76K animals from both the fetal and adult 
cohorts had diminished survival compared to their controls 
(Figure 4A). Mutants from the fetal cohort had a median 
survival of 67 weeks after tamoxifen exposure, whereas 
mutants from the adult cohort had a median survival of 
62 weeks. Both Csf1r-MCM+;E76K mutant cohorts 
had splenomegaly and a small number of animals died 
with enlarged thymuses (Figure 4C–4E). Interestingly, 
the survival of the Csf1r-MCM+;E76K cohorts was not 
different from that of Flt3Cre+;E76K mutants (Figure 4A). 
This was surprising given that the proportion of cells 
with active Cre recombinase activity, as measured by 
the expression of either YFP or GFP, was at least 10-fold 
greater in Flt3Cre+ animals compared with Csf1r-MCM+ 
animals (Figure 4B). This result suggested that either i) 
the morbidity from disease was independent of the mutant 
allele fraction or ii) that there was an unpredictable 
relationship between the presence of the fluorescent 
marker and the expression of Ptpn11E76K.
We therefore proceeded to directly measure the 
frequency of cells that had recombined the Ptpn11LSL-E76K 
Figure 3: Peripheral blood comparison of Csf1r-MCM+ Ptpn11E76K fetal and adult cohorts. (A–F) Animals in the adult 
cohort were exposed to tamoxifen at 4 weeks (n = 12 mutants and 16 WT) (G–L) Animals in the fetal cohort were exposed to tamoxifen 
at E14.5. (n = 7 mutants and 10 WT) A,G) Leukocyte counts. (B, H) Frequency of YFP+ cells. (C, I) platelet counts. (D, J) Frequency 
of myeloid cells. (E, K) Frequency of T-cells. (F, L) Frequency of B cells. Percentages represent each lineage’s proportion among all 
mononuclear cells. P values represent t-tests comparing mutants and controls.
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locus. We designed qPCR primers that would amplify 
the loxP-flanked DNA sequence that must be excised to 
permit transcription of mutant Ptpn11. We sorted YFP+ 
peripheral blood cells from Csf1r-MCM+;E76K animals 
1 week after tamoxifen treatment. 22% of YFP+ myeloid 
cells retained the non-recombined Ptpn11 LSL-E76K 
allele, indicating that YFP had a positive predictor value 
(PPV) of 78% for mutant allele expression (Figure 5A). In 
contrast, the negative predictive value of YFP expression 
for Ptpn11E76K expression was only 47%, as measured 
by the proportion of YFP- cells that had recombined the 
mutant locus (Figure 5A). 32 weeks after tamoxifen, 
the PPV of YFP expression for Ptpn11 recombination 
improved to 96%, albeit the NPV fell to 12% (Figure 5B). 
We repeated this analysis using sorted GFP+ and Tomato+ 
cells from 32 week-old Flt3Cre+;E76K mice (Figure 
5D). The PPV of GFP for mutant allele recombination 
was 99% but the NPV was only 5% (Figure 5D). We 
confirmed that fluorescence expression was an excellent 
predictor of recombination at the Rosa26 locus, indicating 
that YFP and GFP expression were not being silenced in 
our animals (Figure 5C, 5E). These results demonstrate 
that the frequency of Ptpn11E76K-expressing leukocytes 
is much greater than that predicted by our fluorescent 
markers. Additionally, these results show that Csf1r-
MCM+;E76K animals have only marginally fewer mutant-
expressing leukocytes when compared to Flt3Cre+;E76K 
animals.
We proceeded to analyze progenitor populations 
in Csf1r-MCM+;E76K animals from the adult cohort 
to further evaluate their cause of death. 32 weeks after 
tamoxifen injection, mutants had equivalent numbers 
of BM progenitors compared to controls (Figure 6A). 
However, there was an increase in the number of splenic 
LK cells, LSK cells, and HSCs in mutants compared to 
controls (Figure 6B). The most pronounced difference was 
in the frequency of CD45– erythroid progenitors—pro-
erythroblasts (CD71+ Ter119–), basophilic erythroblasts 
(CD71+ Ter119+), and late erythroblasts (CD71low/dim 
Ter119+) (Figure 6C). We proceeded to confirm whether 
progenitors from our model had two pathognomonic 
features of JMML: growth hypersensitivity to GM-
CSF and hyperactive Ras-Erk signaling. We plated 
BM cells at increasing doses of GM-CSF and observed 
that mutant progenitors gave rise to more colonies at 
low cytokine doses compared to controls (Figure 6D). 
Next, we generated BM-derived macrophages from 
mutants and controls and measured phosphorylation 
(p-) of ERK following stimulation with 20 ng/ml GM-
CSF. Mutant macrophages had markedly greater p-ERK 
expression than control macrophages at baseline and up 
to 30min following cytokine stimulation (Figure 6E). As 
expected given the comparable frequency of Ptpn11E76K 
expression, no difference in colony formation and p-ERK 
expression was observed between YFP+ and YFP- cells 
(Supplementary Figures 5–6).
Figure 4: Survival analysis of Ptpn11E76K cohorts. (A) Kaplan–Meier analysis of survival among Ptpn11E76K cohorts driven 
by Flt3Cre, Csf1r-MCM activated at 4 weeks of age, and Csf1r-MCM activated at E14.5. (B) Comparison of the frequency of YFP or GFP 
expression in peripheral blood leukocytes in the indicated cohorts. (C–E) comparison of tissue weights of moribund animals or littermates 
analyzed at the end of the study. P-values represent t-tests comparing each mutant group to the control animals.
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Finally, we proceeded to characterize the 
distribution of leukocytes in tissues of our Csf1r-MCM+ 
adult cohort. Mutant animals had fewer CD8+ BM T-cells 
and fewer CD4+ splenic T-cells compared to controls 
(Figure 7A, 7B). They also had modest expansion of 
splenic CD11b+ Gr1+ neutrophils and CD11c+ MHCII+ 
dendritic cells (Figure 7B, Supplementary Figure 7). We 
proceeded to further evaluate T-cell subsets in mutant 
animals by comparing the relative frequency of naïve vs. 
memory T-lymphocytes. Mutant animals in both the adult 
and the fetal cohorts had markedly diminished CD44-/
low CD62L+ naïve cells among both CD4+ and CD8+ 
T-cells (Figure 7C–7F). We reasoned that this depletion 
of naïve T-cells may prompt an increase in the number of 
T cell progenitors. Indeed, whereas the number of CLPs 
in the BM of mutant animals was not increased (Figure 
5A), there was an marked increase in the frequency of 
early T cell progenitors in the thymus (Lin- cKit+) as 
well as committed CD4- CD8- CD25+ progenitors, DN 
IIb progenitors (CD44+ cKit-), and DN III progenitors 
(CD44– cKit-) (Figure 7G, 7H, Supplementary 
Figure 8).
DISCUSSION
We present the first hematopoietic-restricted animal 
models of Ptpn11E76K that avoid myeloablation. We 
demonstrate that Flt3Cre+;E76K and Csf1r-MCM+;E76K 
mice have a markedly prolonged survival compared with 
previous conditional models that expressed this mutation 
with non-hematopoietic-restricted Cre strains. We 
thereby show that Ptpn11E76K-expressing hematopoietic 
progenitors in mice give rise to an indolent disease that 
has delayed onset of anemia, minimal monocytosis, and 
inconsistent leukocytosis. Rather, the dominant pathology 
of Ptpn11E76K is early-onset thrombocytopenia with 
a marked increase in the frequency of extramedullary 
erythropoiesis.
Figure 5: Differential Cre activity in Rosa26 and Ptpn11 loci. The frequency of non-recombined Ptpn11LSL-E76K alleles was 
measured by qPCR in sorted leukocyte subsets. (A) In Csf1r-MCM+ Ptpn11E76K peripheral blood leukocytes 1 week after tamoxifen 
injection. (B) In Csf1r-MCM+ Ptpn11E76K peripheral blood leukocytes 32 week after tamoxifen injection. (C) PCR analysis of 
recombination of the Rosa26 locus in leukocyte samples shown in panel A. (D) Analysis of sorted GFP+ and Tomato+ peripheral blood 
CD11b+ Gr1+ neutrophils. (E) qPCR analysis of recombination at Rosa26 locus in samples shown in (D).
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Given that JMML’s origin is intimately associated 
with fetal blood development, we sought to compare the 
contribution of fetal and adult hematopoietic progenitors 
to disease. We devised an inducible Cre-loxP strategy 
whereby the timing of tamoxifen administration would 
determine the temporal expression of Ptpn11E76K. 
Previous studies have demonstrated that the transition 
from fetal to adult hematopoiesis in the mouse is 
complete by 4 weeks of age [28]. The corresponding 
transition in humans was measured to occur at 2 years of 
age [29, 30]. We therefore chose to induce Cre activity 
at our model at E14.5 or at 4 weeks of age to target 
fetal and adult progenitors, respectively. We chose the 
Csf1r-MCM strain because this promoter is active in 
hematopoietic progenitors, including HSCs [31]. Our 
results confirm that tamoxifen injection at E14.5 and 4 
weeks of age can durably target a subset of hematopoietic 
progenitors, as measured by the expression of YFP. We 
therefore proceeded to generate fetal and adult cohorts of 
Csf1r-MCM+;E76K animals and compare their disease 
progression with that of Flt3Cre+;E76K animals.
Mutants in our fetal cohort developed monocytosis 
more rapidly than mutants in the adult phase, and this 
myeloid-biased differentiation continued until 52 weeks 
of age. This is consistent with the greater proliferative 
and myeloid-colony forming potential of fetal progenitors 
compared with adult progenitors [23, 32]. These findings 
support the hypothesis that the fetal hematopoietic 
microenvironment is more prone to the development of 
JMML-like myeloproliferative features. Nevertheless, 
the overall burden of disease was minimal; both fetal and 
adult Csf1r-MCM+;E76K cohorts had delayed onset of 
anemia, minimal monocytosis, and lacked leukocytosis. 
This suggests that the morbidity elicited by hematopoietic-
restricted Ptpn11E76K is considerably less than that of 
previous models, such as Mx1Cre+;Ptpn11E76K, wherein 
oncogene expression was not limited to blood cells. As 
such, our findings are consistent with the recent findings 
that Ptpn11E76K-expressing BM stromal populations 
exacerbate MPN [19]. We acknowledge that we cannot 
exclude the possibility that altered housing conditions or 
animal microbiomes contribute to differences between our 
Figure 6: Progenitor analysis in Csf1r-MCM+ Ptpn11E76K. All animals were exposed to tamoxifen at 4 weeks of age and 
analyzed 32 weeks later. (A) Abundance of BM progenitors. (B) Abundance of splenic progenitors. (C) Abundance of erythroid progenitors 
in the spleen. (D) Methylcellulose colony assays were performed at indicated doses of GM-CSF. Colonies were scored on day 7 (n = 6 
biologic replicates/group). (E) p-ERK expression in BM-derived macrophages following stimulation with GM-CSF, as measured by 
intracellular flow cytometry (n = 3 biologic replicates/group). Fluoresence minus one (FMO) controls were used to define background 
fluorescence absence of p-ERK staining. All p-values represent t-tests comparing mutants and controls.
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E76K model and those reported previously. Nevertheless, 
our results strongly advocate for future studies of MPN 
and leukemia to use techniques that can distinguish 
hematopoietic from non-hematopoietic burdens of disease.
Fetal and adult Csf1r-MCM+;E76K cohorts 
had similar survival following exposure to tamoxifen. 
This suggests that the early onset of monocytosis 
in the fetal cohort was not a major determinant of 
morbidity. Rather, thrombocytopenia and expanded 
extramedullary erythropoiesis were the most pronounced 
phenotypes in our adult cohort mutants and likely had 
the greatest contribution to mortality. These findings are 
consistent with earlier studies that have noted expanded 
extramedullary hematopoiesis and defective erythropoiesis 
in JMML animal models [9, 11, 33]. One potential 
mechanism for this mobilization is a pro-inflammatory 
BM niche that provokes extramedullary seeding of 
progenitors. It is notable, however, that our models did 
not show the same degree of monocytosis as is observed 
in JMML patients. One potential explanation are the sub-
Figure 7: T-lymphocyte analysis in Csf1r-MCM+ Ptpn11E76K. All animals were exposed to tamoxifen at 4 weeks of age and 
analyzed 32 weeks later, unless indicated. (A, B) Frequency of myeloid cells, dendritic cells, B-cells, and T- cells in the BM and spleen of 
mutants and littermates. (C, D) Frequency of naïve and effector CD4+ cell subsets with representative gating. (E, F) Frequency of naïve 
and effector CD8+ cell subsets with representative gating. (G, H) Distribution of T-lymphocyte progenitors in the thymuses of mutants 
and littermates. DP, CD4 CD8 double positive. DN, double negative. P-values in panels C and E represent two-tailed t-tests comparing the 
frequency of naïve T cells.
Oncotarget21840www.oncotarget.com
clonal secondary mutations in Ras signaling mediators 
that confer a worse prognosis among a subset of JMML 
patients [1–3]. In contrast, our models expressed a single 
oncogenic mutation and it is likely that the presence of 
additional oncogenes in our mice would evoke a more 
rapidly-progressing JMML-like MPN. 
We expected Flt3Cre and Csf1r-MCM models 
of Ptpn11E76K to produce markedly different MPN 
manifestations. Flt3Cre is constitutively active, indicating 
that the mutation will be expressed de novo each time 
an HSC differentiates through a Flt3+ intermediate. 
Furthermore, Flt3Cre is highly efficient and targets 
approximately 90% of leukocytes.  In contrast, Csf1r-
MCM is only active in Csf1r+ cells in the presence of 
tamoxifen. As such, mutagenesis should occur during 
a single brief interval of time in a small subset of cells. 
We reasoned that this strategy would more accurately 
represent the clonal nature of leukemogenesis whereby 
a handful of oncogene-expressing cells expand amidst 
neighboring WT cells.
Our lineage trace of Csf1r-MCM+;Rosa26YFP 
mice confirmed that this Cre could target a small subset 
of hematopoietic progenitors (Figure 2). Furthermore, 
we observed an expansion of mutant YFP+ cells in our 
adult Csf1r-MCM+;E76K cohort to 24 weeks (Figure 
4B). However, the frequency of YFP+ cells plateaued 
at 8% and did not increase further up to at least 52 
weeks of age. This plateau prompted us to evaluate the 
faithfulness of our fluorescent reporters for oncogene 
expression. We determined that the majority of YFP- 
cells had inappropriately recombined their Ptpn11 LSL-
E76K allele. As a result, there was no correlation between 
fluorescence and oncogene expression. Our results further 
showed that Flt3Cre and Csf1r-MCM models had nearly-
identical proportions of Ptpn11E76K-expressing blood 
cells. As such, we could not evaluate whether near-clonal 
expression of Ptpn11E76K is sufficient to give rise to MPN 
in a mouse model. We do demonstrate, however, that both 
Csf1r-MCM and Flt3Cre have different recombination 
efficiencies at different loci and that oncogene expression 
cannot be inferred from fluorescence-based lineage trace 
studies. 
The role of T cells in our model is intriguing. We 
noted that Flt3Cre+;E76K and Csf1r-MCM+; E76K 
models had decreased frequency of T-lymphocytes. 
CD4+ cells were preferentially reduced compared with 
CD8+ cells. Furthermore, the distribution of CD4+ and 
CD8+ cells favored effector cells (CD44hi CD62L neg/lo) 
whereas there was a paucity of naïve cells (CD44 low/neg 
CD62L+). This suggests that T-cells are being activated 
by antigen presenting cells, leading to their exhaustion 
and depletion. This is supported by our findings in the 
thymus, where we observed a relative increase of CD4- 
CD8- progenitors, including cKit+ CD44+ CD25- early 
thymic progenitors. This suggests that the thymus of 
mutant animals may undergo greater turnover, which 
may predispose to tumorigenesis. Indeed, we observed 
that 25% of mutant animals in our studies died with large 
thymuses, which is suggestive of T-ALL. 
Our T-cell findings have notable parallels in JMML 
patients. Occasionally, these children acquire T-ALL 
either concurrently with their MPN or after the resolution 
of their myeloid disease [18, 34–36]. Our observation of 
decreased naïve peripheral T cells and increased thymic 
precursors may provide a mechanistic explanation for 
this association. Admittedly, it is rare for a patient to have 
both JMML and T-ALL. However, this low rate is not 
surprising given that T cells in most JMML patients do 
not express the disease-initiating mutation [1, 37]. This 
lack of expression may be the result of a block in T cell 
maturation among mutation-expressing progenitors. This 
is supported by case reports that have suggested JMML 
patients have decreased T cell frequencies compared with 
healthy controls [38, 39]. Alternatively, the kinetics of T 
cell development in the thymus may delay the presence of 
mutated T cells in the periphery as compared with mutated 
myeloid progeny. It will be informative for future studies 
to definitively measure the frequency of T cells in JMML 
patients and to assess the relative contribution of their 
CD4+ and CD8+ cells as well as their naïve and effector 
subsets.
In summary, we present the first hematopoietic-
restricted model of Ptpn11E76K expression that does 
not rely on transplantation. We demonstrate that in 
utero mutations in fetal progenitors result in more 
rapid monocytosis compared with mutations in adult 
progenitors. Nevertheless, our models had indolent MPN 
progression as measured by anemia, leukocytosis, and 
monocytosis. Instead, our models developed splenomegaly 
due to pronounced extramedullary erythropoiesis and 
thrombocytopenia. Finally, we demonstrate mutant mice 
to have a paucity of T lymphocytes, most notably a deficit 
of CD4+ and memory T cells. Our findings reveal the 
temporal progression of MPN in models of JMML and 
suggest that abnormal extramedullary erythropoiesis and 
T-lymphopoesis may have a significant contribution to 
morbidity in JMML patients.
MATERIALS AND METHODS
Study approval
Animal studies were approved by the IACUC at the 
Indiana University School of Medicine.
Mice
C57BL/6J mice were bred in-house. 
Flt3Cre+;ROSAmTmG/mTmG mice were a kind gift from Dr. 
Slava Epelman (University of Toronto). LSL-PTPN11E76K/+ 
mice were obtained from Dr. Cheng-Kui Qu (U. Emory, 
Atlanta, GA).  ROSAYFP/YFP mice were obtained from Dr. 
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Anthony Firulli (IUSM, Indianapolis, IN). CSF1R-Mer-
Cre-Mer mice (#019098) were purchased from Jackson 
Labs and were back-crossed onto the C57B6 background 
for 6 generations. Mice were identified by ear notches or 
toe clips. Genotyping was performed with conventional 
PCR using primers listen in the Supplement. 
Timed matings
Male studs (10–26 weeks of age) were housed 
in separate cages and mated after at least 2–3 days of 
acclimatization to their cage. In the evening one or two 
female mice (8–26 weeks of age) were moved to the stud 
cage. The following morning, successful matings were 
confirmed by visual inspection of a vaginal plug and 
assigned a gestational age of E0.5. 
Tamoxifen treatment
To induce recombinase activity in utero, pregnant 
dams were injected i.p. with 75 ug/g 4-hydroxy tamoxifen 
(Sigma #H6278) along with 37.5 ug/g progesterone 
(Sigma #P0130). Litters of tamoxifen-treated dams were 
routinely delivered by C-section on E19.5 and raised by 
foster females.
Cell isolations
Blood was collected into EDTA-coated tubes and 
analyzed using the HemaVet 950FS hematology analyzer 
(Drew Scientific). Mouse tissues were kept on ice in PBS 
+ 2 mM EDTA. Bone marrow cells were flushed from 
hindlimb bones. Spleens and thymuses were triturated with 
glass cover slides. BM stromal populations were isolated 
by incubating flushed bones in 22 U/ml collagenase type 
2 (Worthington Biochemical #LS004177) for 45 min at 
37° C.
Flow cytometry
Cells were stained at a concentration of 1–5 × 107/ml 
in PBS +2% FBS + 2 mM EDTA. Antibody concentrations 
were determined experimentally. If required, cells were 
fixed in 1% PFA (Fisher #50-980-487). For Intracellular 
phospho-flow, cells were stimulated in an Eppendorf tube 
with GM-CSF (Peprotech #315-03), fixed in 1% PFA 
for 15 min, and permeabilized using BD Perm Buffer 
III (#558050). Stained cells were analyzed using the BD 
LSR Fortessa, BD FACS CANTO II, or BD Accuri C6. 
Cell sorting was performed on a BD FACSAria. Post 
run analysis was performed using FlowJo (Treestar). 
Percentages in graphs represent each lineage’s frequency 
among live mononuclear cells, as determined by FSC and 
SSC gating. 
Methylcellulose progenitor assays
5 × 104 BM mononuclear cells were plated in 1 ml of 
methylcellulose medium (40% ES-Cult M3120 (Stem Cell 
Technologies), 30% FBS (HyClone), 220 U/ml Pen/Strep, 
1.2 mM L-Glutamine, and 440 nM β-Mercaptoethanol) 
and defined concentration of murine GM-CSF (Peprotech 
#315-03). Colonies were counted 7 days after plating.
qPCR
Genomic DNA was isolated from cells using the 
Qiagen DNeasy Blood & Tissue Kit (#69504). Samples 
were prepared using FastStart Universal SYBR Green 
Master (Roche #04913850001) and were run on a 7500 
Real-Time PCR System (Applied Biosystems). Primer 
sequences are listed in the Supplement.
Histology
Mouse femurs were fixed in 4% phosphate 
buffered formaldehyde overnight, stored in 70% ethanol, 
demineralized with EDTA, paraffin embedded, sectioned 
to 5 µm, and stained using hematoxylin and eosin.
Statistics
Statistical analysis was performed using GraphPad 
Prism 7.0. P values comparing mutant and littermate 
groups were calculated using two-tailed Student’s t tests, 
one-way ANOVA, Mantel Cox log rank tests, or chi-
squared test. P values < 0.05 were considered significant. 
All error bars represent SD. P-value notations: ns p > 0.05, 
*p < 0.05, **P < 0.01, ***p < 0.001.
Abbreviations
4OHT: 4 hydroxy-tamoxifen; CMoP: common 
monocyte progenitor; CMP: common myeloid progenitor; 
Csf1r: colony stimulating factor 1 receptor; DN: double 
negative (CD4– CD8–); DP: double positive (CD4+ 
CD8+); EC: endothelial cells; GFP: green fluorescent 
protein; GM-CSF: granulocyte-macrophage colony 
stimulating factor; GMP: granulocyte-macrophage 
progenitor; HSC: hematopoietic stem cell; JMML: 
Juvenile Myelomonocytic Leukemia (JMML); LK: 
Lin– cKit+ cells; LSK: Lin- cKit+ Sca1+ cells; 
MCM: Mutated estrogen receptor – Cre – Mutated 
estrogen receptor; MDP: myeloid-dendritic progenitor; 
MEP: megakaryocyte-erythrocyte progenitor; MPN: 
myeloproliferative neoplasm; MSPC: mesenchymal stem/
progenitor cell; NPV: negative predictive value; OB: 
osteoblast; PPV: positive predictive value; Ptpn11: protein 
tyrosine phosphatase 11; YFP: yellow fluorescent protein.
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